Case Overview: A 71-Year-Old Woman with Metastatic Endometrial Cancer
Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.
Case History
June 2021
A 71-year-old postmenopausal woman presented with intermittent uterine bleeding, increased urinary frequency, and cramping over the past 6 months.
- She noted that she underwent menopause at 52 years of age
- She is married and has 2 adult children
- PMH: T1D since childhood, well-controlled
- PE: Notable for uterine tenderness upon palpation
- ECOG PS= 1
- Chest/abdomen/pelvis CT revealed uterine and bladder masses
- CA-125= 38.6 U/mL
- Endometrial biopsy results:
- Endometrioid adenocarcinoma
- FIGO stage IVA
- Grade 3 (poorly differentiated)
- IHC testing revealed mismatch repair proficiency (pMMR) and estrogen receptor (ER) negativity
July 2021:
- Patient started carboplatin/paclitaxel (6 cycles), which was well-tolerated
- Patient was scheduled for follow-up visits every 3 months after completion
May 2022 (6 months post–chemotherapy completion):
- CA-125 level increased to 42.1 U/mL
- CT revealed that the previous bladder metastatic mass increased slightly in size
- The patient discussed targeted systemic therapy options with her clinician, and she expressed the desire to spend as much time as possible with her grandchildren.
- They jointly decided to trial lenvatinib/pembrolizumab, with instructions to continue follow-up visits every 3 months.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in Endometrial Cancer
September 18th 2024The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.
Read More
